Autologous HB-adMSCs not checked

Hope Biosciences LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Hope Biosciences autologous adipose-derived mesenchymal stem cells”In the company’s words, NCT05951777 on ClinicalTrials.gov
Tested for
Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Traumatic Brain Injury
Main trialPhase 2
“This protocol is part of a clinical study to evaluate efficacy and safety of multiple intravenous administrations of HB-adMSCs for the treatment of Multiple Sclerosis.”In the company’s words, NCT06800404 on ClinicalTrials.gov

Other drugs for Relapsing Remitting Multiple Sclerosis (RRMS)

All 12 drugs for Relapsing Remitting Multiple Sclerosis (RRMS)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Jan 2027 "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
Phase 2Recruiting Dec 2027 Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Autologous HB-adMSCs

Following is part of Solo: you see every change to Autologous HB-adMSCs the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in